Optimizerx Corporation (OPRX)
NASDAQ (CM) NASDAQ (CM) Primary 
OPRX vs. GDRX: Which Health Tech Stock Has Stronger Revenue Momentum?
OPRX is growing faster with rising subscription revenues and strong pharma demand, while GDRX lags due to slower consumer growth.
OptimizeRx Bets on AI and Workflow Integration: Will This Pay Off?
OPRX doubles down on AI and subscriptions, but margin mix and retention risks loom over its platform transformation.
Can OptimizeRx Maintain Profit Growth Amid Evolving Pharma Spend?
OPRX raised guidance after record Q1 EBITDA, but pharma budget shifts and margin mix pose new challenges ahead.
OPRX Shares Rise 69.3% in 3 Months: Time to Bet on the Stock?
OPRX surged 69.3% in three months as rising contracted revenue and subscription gains boost confidence and guidance.
Here's Why OptimizeRx Corp. (OPRX) is a Great Momentum Stock to Buy
Does OptimizeRx Corp. (OPRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Earnings Estimates Rising for OptimizeRx (OPRX): Will It Gain?
OptimizeRx (OPRX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
OptimizeRx Corporation (OPRX) Q1 2025 Earnings Call Transcript
OptimizeRx Corporation (NASDAQ:OPRX ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Steve Silvestro - Chief Executive Officer Edward Stelmakh - Chief Financial Officer Andrew D'Silva - Senior Vice President, Corporate Finance Conference Call Participants Ryan Daniels - William Blair David Grossman - Stifel Richard Baldry - ROTH Capital Maxwell Michaelis - Lake Street Capital Markets Constantine Davides - Citizen Jeff Garro - Stephens Operator Good afternoon, everyone, and thank you for joining OptimizeRx First Quarter Fiscal 2025 Earnings Conference Call. With us today is Chief Executive Officer, Steve Silvestro, he's joined by Chief Financial Officer; Ed Stelmakh; Chief Legal Officer, Marion Odence-Ford; and Senior Vice President of Corporate Finance, Andrew D'Silva.
OptimizeRx Corp. (OPRX) Beats Q1 Earnings and Revenue Estimates
OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of a loss of $0.11 per share. This compares to loss of $0.11 per share a year ago.
OptimizeRx Clocks Double-Digit Revenue Growth In Q4, Forecasts Sales Of At Least $100 Million
OPTIMIZERx Corp. OPRX, a health care technology firm, reported on Wednesday fourth-quarter sales of $32.32 million, up 14% year-over-year, beating the consensus of $30.36 million.
OptimizeRx Corporation (OPRX) Q4 2024 Earnings Call Transcript
OptimizeRx Corporation (NASDAQ:OPRX ) Q4 2024 Results Conference Call March 12, 2025 8:30 AM ET Company Participants Steve Silvestro - President Edward Stelmakh - Chief Financial Officer and Chief Operational Officer Andrew D'Silva - Senior Vice President of Corporate Finance Conference Call Participants Jared Haase - William Blair Anderson Schock - B. Riley Constantine Davides - Citizens JMP Richard Baldry - ROTH Capital David Grossman - Stifel Financial Eric Martinuzzi - Lake Street Jeff Garro - Stephens, Inc Operator Good morning, everyone, and thank you for joining OptimizeRx's Fourth Quarter and Full Year Fiscal 2024 Earnings Conference Call.
OptimizeRx Corp. (OPRX) Q4 Earnings and Revenues Beat Estimates
OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.26 per share a year ago.
OptimizeRx initiated with an Equal Weight at Stephens
Stephens initiated coverage of OptimizeRx with an Equal Weight rating and $5.50 price target. The firm says the company's "evolving" direct-to-consumer business model toward self-service may create headline risk to net revenue retention. Stephens still needs clarity on the company's return to growth and evolution of the business model that "cements OptimizeRx's place in the value chain."
